SRRK — Scholar Rock Holding Corporation

Summary of Scholar Rock (SRRK) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Scholar Rock ended Q3 2025 with $369.6 million in cash and cash equivalents.
• Operating Expenses: Reported operating expenses were $103 million, including $18.3 million in non-cash stock-based compensation. Excluding this, operating expenses were $85.3 million.
• Capital Raise: The company strengthened its balance sheet by adding $141.7 million through an at-the-market (ATM) offering and a $50 million drawdown from an existing debt facility.
• Cash Runway: The current cash balance is expected to fund operations into 2027, with additional cash anticipated from warrant exercises.

2. Strategic Updates and Business Highlights

• Apitegromab: The company is focused on bringing apitegromab, a treatment for spinal muscular atrophy (SMA), to market following a complete response letter (CRL) from the FDA due to issues at a third-party manufacturing facility.
• Regulatory Engagement: A constructive Type A meeting with the FDA was held, where Novo Nordisk, the facility owner, indicated readiness for reinspection by year-end.
• Supply Chain Redundancy: Scholar Rock is adding a second fill/finish facility to mitigate risks associated with the primary facility's compliance issues.
• Pipeline Development: The company is advancing its pipeline, including a Phase II study for apitegromab in infants and toddlers and the initiation of clinical development for SRK-439, a new myostatin inhibitor.

3. Forward Guidance and Outlook

• Resubmission Timeline: The company plans to resubmit the Biologics License Application (BLA) for apitegromab in 2026, contingent on a successful reinspection of the Bloomington facility.
• Market Potential: There is a significant opportunity in the SMA market, with approximately 35,000 patients eligible for apitegromab.
• Commercial Readiness: The company is enhancing its engagement with treatment centers and physicians to prepare for a successful launch upon approval.

4. Bad News, Challenges, or Points of Concern

• Regulatory Setback: The complete response letter from the FDA was a significant setback, highlighting issues with the manufacturing facility's compliance.
• Operational Risks: Transitioning between manufacturing facilities poses operational risks, although the company is working to ensure a seamless process.
• Market Competition: The SMA treatment landscape is competitive, with existing therapies already generating approximately $5 billion in annual revenue globally.

5. Notable Q&A Insights

• Financing Strategy: The company aims to prioritize non-dilutive financing options, such as extending its loan facility, before considering equity financing.
• Inspection Readiness: There is optimism regarding the remediation efforts at the Bloomington facility, with Novo Nordisk actively working with external consultants to ensure compliance.
• Patient Engagement: The sales team is actively identifying potential patients and engaging with treatment teams to enhance understanding of the patient journey and improve uptake post-launch.
• Regulatory Dynamics: The FDA's approach to the resubmission and potential timelines remains dynamic, with the company committed to collaborating closely with the agency.

This summary encapsulates the key points from Scholar Rock's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.